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Caspofungin in the treatment of candidosis 
and aspergillosis 
Johan Maertens(l) and Marc Boogaerts(l) 
Antifungal agents can be classified by their site of action in fungal cells, which can have important implications for 
both efficacy and tolerability. Currently available agents include the polyenes, nucleoside analogs, and the azoles. 
With the exception of 5-fluorocytosine, all agents act by interfering with the structural or functional integrity of the 
fungal plasma membrane. However, the non-selective nature of this therapeutic target results in concomitant cross- 
inhibition (or toxicity) in mammalian cells. New compounds that interfere with the fungal cell wall-a target not 
present in mammalian cells-therefore constitute an important focus of current clinical research. Caspofungin, the 
first representative of a new class of antifungals that inhibit B-(1,3)-D-glucan synthesis, exerts potent activity against 
Candida and Aspergihs spp. and appears to be generally well tolerated. This paper reviews the data on caspofungin. 
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INTRODUCTION 
The incidence of invasive fungal infections has increased 
dramatically over the last two decades, due in large 
part to an increased number of immunocompromised 
patients, and increased use of invasive pr0cedures.l 
Mycoses with emerging pathogens such as Aspergillus 
and Candida spp. have become important causes of 
morbidity and mortality. The unacceptable high crude 
mortality rate of these infections-up to 90% for 
invasive aspergillosis-results in part from difficulties in 
obtaining a reliable diagnosis at an early stage of the 
disease.2-6 Hence, generalized prophylaxis and empirical 
antifungal therapy have been introduced in an effort to 
overcome the diagnostic obstacles, especially since the 
early start of adequate therapy appears to be crucial in 
improving the detrimental outcome of established 
disease.7 The implementation of sensitive, new diagnostic 
tools with good predictive value, such as galactomannan 
antigen detection, high-resolution pulmonary CT scan- 
ning, and detection of fungal DNA or metabolites, may 
allow a more targeted pre-emptive approach, directed 
towards true high-risk patients.*-lo 
The high mortality rate of these infections results 
also from shortcomings in the available therapeutic 
arsenal.11 Amphotericin B deoxycholate, flucytosine 
and itraconazole are associated with low success rates, 
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and are hampered by serious infusion- or drug-related 
toxicity, by hazardous drug interactions, by pharmaco- 
kinetic problems, and by the development of resistance.12 
Fluconazole is devoid of any activity against Aspevgillus 
spp., and its widespread (prophylactic) use has resulted 
in increasing reports of treatment failure and resistant 
Candida organisms, most notably-although not exclu- 
sively-in HIV-infected patients.13 Lipid formulations of 
amphotericin B display a better toxicity profile, and 
therefore, in spite of their high acquisition cost, may 
even be cost-effective when compared with conventional 
amphotericin B.14,1j It must, however, be mentioned that 
each lipid formulation (liposomal amphotericin B, 
amphotericin B lipid complex (ABLC), and amphotericin 
B colloidal dispersion (ABCD)) has markedly distinct 
biochemical, pharmacokinetic and pharmacodynamic 
properties. Also, neither ABCD nor ABLC shows a 
reduced incidence of acute infusion-related side effects 
compared to the parent compound.16,r7 
In the 1970s researchers identified several classes of 
naturally occurring compounds that could inhibit fungal 
cell wall synthesis, including the echinocandin family 
of antifungals (echinocandins, cilofungin, aculeacins, 
pneumocandins, mulundocandins, and WF-11899).rs The 
echinocandins and pneumocandins, structurally related 
lipopeptides with a cyclic peptide core and a number of 
attached lipid chains, proved to be fungicidal in vitro 
and in animal models. Although the natural product 
echinocandin B, the first antifungal representative of 
this class, induced hemolysis, simple substitution of the 
linoleoyl group with synthetic side-chains resulted in 
non-lytic analogs. In particular, cilofungin (LY121019), 
the 4-n-octyloxybenzoyl ECB derivative, appeared very 
promising; the drug was more than lo-fold less hemolytic 
than the parent compound, and retained excellent tidal 
activity against Candida spp. and A. furnigatus. How- 
ever, cilofungin was abandoned in phase II clinical trials, 
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because of renal acidosis associated with the polyethylene 
glycol vehicle in which the drug was given.19 
Several companies have continued their search 
for semisynthetic analogs with improved pharmacologic 
properties and identified three water-soluble bioactive 
derivatives: caspofungin (derived from pneumocandin 
Bo, Merck & Co. Inc.), anidulafungin (derived from 
echinocandin B, Versicor), and micafungin (Fujisawa). 
These analogs are more potent and display a broader 
antifungal spectrum than their respective natural 
counterparts. 2o This review aims at summarizing the 
clinical development and current status of caspofungin, 
the first in a new class of antifungals, in the treatment of 
Candida and Aspergillus infections. 
MECHANISM OF ACTION 
All candins exert their action through inhibition of the 
synthesis of glucan, a critical fungal cell wall component 
not present in mammalian cells. These agents primarily 
act as specific and non-competitive inhibitors of p-(1,3)- 
D-glucan synthase. The resulting depletion of cell wall 
glucan leads to osmotic shock, ballooning, and ultimately 
lysis of the cell. 21 This is distinct from the azoles and 
polyenes, which target cell membrane ergosterol (Table 
1). 
IN VITRO ACTIVITY 
Caspofungin (Figure 1) displays potent in vitro and 
in vivo activity against a wide range of yeast and 
fungi, including most clinically relevant Candida and 
Aspergihs spp. A large number of in vitro susceptibility 
studies have shown that caspofungin is equal to or more 
potent than the azoles itraconazole and fluconazole, the 
investigational triazoles voriconazole, posaconazole and 
ravuconazole, amphotericin B, flucytosine and other 
investigational candins (e.g. LY303366) against Candida 
albicans, Candida glabrata, and Candida tropicalis.22-26 
Caspofungin MIC90 values against azole-susceptible 
strains are 1 ug/mL or less; one study even found that 
all Cundida isolates were inhibited at a concentration 
of 0.78 ug/mL or less. 24 Given its novel mechanism of 
action, caspofungin could be expected to retain activity 
against Candida strains with acquired or intrinsic 
resistance to the currently available classes of anti- 
fungals. MIC values against amphotericin B-, flucytosine- 
or azole-resistant isolates of Candida albicans, Candida 
glabrata, Candida tropicalis and Candida lusitaniae 
are consistently less than 2 ug/mL. The activity against 
Candida krusei is comparable to that of amphotericin B, 
itraconazole, and posaconazole. However, caspofungin 
has less or poor in vitro activity against Cundida 
parapsilosis (MI&J 0.5-4 ug/mL) and Candida guiller- 
mondii (MICpo 0.5-S ug/dL).27 
Caspofungin shows enhanced in vitro activity 
(MIC9o 0.12 ,ug/mL) against clinical isolates of Asper- 
gillus, including A. fumigatus and A. jlavus, compared 
with itraconazole, amphotericin B, and flucytosine.26 
These results have been confirmed with Aspergillus 
isolates obtained from patients included in phase III 
clinical trials; for all species, MICso geometric means are 
below 1 ug/mL at 24 h. 
The in vitro activity of caspofungin has been con- 
firmed in several animal models.28-31 Efficacious in 
vivo activity against Candida spp. (including Candida 
glabrata and Candida krusei) has been shown in a range 
of murine models. Even in the most stringent model of 
disseminated candidiasis, a chronically pancytopenic 
mouse model, caspofungin prolonged survival compared 
to amphotericin B, and sterilized the kidneys, in mice 
with disseminated infection, even when therapy was 
delayed for 24 h. This underlines the fungicidal activity 
against Candida spp. Caspofungin showed a dosage- 
dependent tissue clearance of Candida albicans in liver, 
spleen, kidney, brain, vitreous and lung in a persistently 
neutropenic rabbit mode1.32 
When compared to controls, caspofungin also signi- 
ficantly prolonged the survival of immunosuppressed 
and neutropenic mice with disseminated/pulmonary 
aspergillosis. It is more difficult to characterize the tidal 
nature of the activity against Aspergihs. In the presence 
of caspofungin, blunting and abnormal branching of 
the hyphae in actively growing areas of the cell are 
Table 1. Mechanisms of action of antifungal agents: implications for efficacy 
Agent 
Site of action 
on the fungal cells Activity Clinical implications 
Amphotericin B Membrane Binds to ergosterol; Potent broad-spectrum 
causes cell death fungicidal activity 
Azoles Membrane Inhibits CYP 450 enzyme 
responsible for ergosterol 
synthesis; damages cytoplasmic 
membrane 
Fungistatic activity of 
variable potency and 
spectrum 
Caspofungin Wall Inhibits glucan synthesis; 
disrupts cell wall 
structure and ultimately 
causes lysis of cell 
Potent broad-spectrum 
antifungal activity; 
potential for additive 
effects in combination 
therapy 
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Figure 1. Caspofungin. 
observed, primarily at the tips and branching points. 
These observations are consistent with the mechanism 
of action, but do not fit the classical definitions of 
fungicidal or fungistatic. However, data from human and 
animal models show that the drug is efficacious, even in 
animals with prolonged immunosuppression. Contrary 
to the results of Candida animal studies, reduction of 
tissue colony-forming units (CFUs) correlates poorly 
with fungal burden in Aspergillus models. Using a 
quantitative PCR-based assay (qPCR) to monitor 
disease progression and measure drug efficacy, Bowman 
et al demonstrated that both caspofungin and ampho- 
tericin B reduced the A. fumigatus burden in infected 
kidney to the limit of detection for the qPCR assay.33 
Caspofungin was also extremely potent in the 
prevention and therapy of pulmonary pneumocystosis34 
in immunocompromised animal models, and prolonged 
survival and reduced tissue burden in murine histo- 
plasmosis. 31 Caspofungin does not have clinically useful 
activity against Cryptococcus neoformans.28 
In most studies, susceptibility testing was performed 
according to a modification of both the National 
Committee for Clinical Laboratory Standards (NCCLS) 
method M38-P (for Aspergillus spp.) and method M27- 
A (for Candida spp.). It is important to remember that 
in vitro susceptibility testing for echinocandins has not 
yet been standardized. Therefore, translation of in vitro 
testing results into in vivo activity remains troublesome. 
For instance, in the randomized invasive candidiasis 
study, caspofungin MICs did not predict microbiological 
outcome;35 the drug proved to be highly effective against 
Candida spp. with reduced in vitro susceptibility, in- 
cluding Candida pavapsilosis.36 More recently, alter- 
native methods based on calorimetric assays have been 
suggested.37 
To date, there has been no antagonism noted in 
preclinical studies between caspofungin and other 
antifungal therapies. Studies evaluating synergy and 
additivity with caspofungin are being explored in vitro 
and in animal models.38 As demonstrated by Bartizal 
et al, exposing Candida albicans isolates to subinhibitory 
concentrations of caspofungin did not induce resistance, 
even after 40 passages. 39 Echinocandin resistance outside 
the laboratory has not yet been reported.21 
HUMAN PHARMACOKINETICS 
Caspofungin is a very large molecule developed for 
parenteral use only. In animal studies, oral bioavail- 
ability appeared to be extremely poor; less than 0.2% 
of the drug was absorbed following an oral dose of 
50 mg/kg. Metabolism and excretion are very slow 
processes. Caspofungin is extensively bound to albumin 
(> 95 %), and plasma pharmacokinetics are primarily 
controlled by the rate of distribution from plasma into 
tissues. Tissue-to-plasma ratios for AUC24 following 
intraperitoneal administration of [3H]MK-0991 (1 mg/kg) 
in mice were 16, 3 and 2 for liver, kidney and large 
intestine, respectively, and 0.3, 0.2 and 0.06 for heart, 
thigh and brain, respectively. The exposure of the small 
intestine, lung and spleen was similar to that of plasma.40 
Since the elimination occurs in the absence of 
distribution equilibrium, the true volume of distribution 
cannot be estimated. Caspofungin displays non-linear 
pharmacokinetics, with moderate accumulation with 
multiple dosing. 41,42 Average concentrations at steady 
state with a 50-mg daily regimen are above the target 
concentration of 1 ug/mL for the entire 24-h dosing 
interval (determined from in vitro susceptibility testing 
of clinically relevant fungal isolates) by day 2; a loading 
dose of 70 mg on day 1 to reach steady state faster 
is recommended for the treatment of Aspergillus 
infections.43 Higher doses of caspofungin, given intra- 
venously as single 150-mg and 210-mg doses or as 
multiple daily lOO-mg doses, have been evaluated in 
adult volunteers, and proved to be well tolerated. 
Following multiple daily doses of 100 mg, the AUC24 
was approximately 2.5 times that with the 50-mg daily 
regimen. 44 Unfortunately, information on tissue concen- 
tration in humans and mode of action in human tissue is 
not yet available. 
Caspofungin undergoes spontaneous chemical 
degradation to an open-ring compound, followed by 
further peptide hydrolysis and N-acetylation.45 Plasma 
elimination is slow, with a clearance of lo-12 mL/min. 
Following single l-h infusions in healthy men, plasma 
concentrations decline in a polyphasic manner: a short 
alpha-phase occurs immediately post-infusion, followed 
by a beta-phase with a half-life of 9-11 h, and an 
additional gamma-phase with a half-life of 45 h. This 
profile allows once-daily dosing. Four weeks after the 
intravenous administration of radiolabeled caspofungin, 
approximately 75% of the dose was recovered, equally 
divided between urine (41%) and feces (34%). Excretion 
is slow, and the terminal half-life of radioactivity was 
12-15 days. Approximately 1.4% of the dose is excreted 
as parent drug in urine, suggesting that the primary 
route of excretion is hepatic.42 
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In patients with mild (Child-Pugh score 5-6) and 
moderate (Child-Pugh score 7-9) hepatic impairment, 
the AUC is increased by about 20% and 75%, 
respectively. To date, there are no clinical data on severe 
hepatic insufficiency (score >9). A reduction of the 
maintenance dose to 35 mg daily in moderate hepatic 
disease provides an AUC similar to that obtained in 
subjects with normal hepatic function receiving the 
standard regimen. 
There are no clinically significant alterations of 
pharmacokinetics in patients with mild, moderate, 
advanced or end-stage renal insufficiency. Therefore, 
no dose adjustment is necessary for patients with any 
degree of renal impairment. Caspofungin is not removed 
from the blood by hemodialysis or ultrafiltration; supple- 
mentary dosing is not required following hemodialysis. 
There are no clinically meaningful alterations in 
pharmacokinetics with age, gender, or race. Caspofungin 
has not yet been sufficiently studied in pediatric 
patients, *46 its use in patients under 18 years of age is 
therefore not recommended. There are no well-controlled 
studies in pregnant women, and it is not known whether 
caspofungin is excreted in human milk. 
DRUG INTERACTIONS 
In vitro studies have shown that caspofungin is neither 
an inhibitor of nor a substrate for an enzyme in the cyto- 
chrome P450 system. Co-administration of caspofungin 
and itraconazole did not alter the pharmacokinetics of 
either drug, suggesting that caspofungin is not subject 
to drug interactions based on CYP3A4 inhibition.43 
Caspofungin also did not influence the pharmacokinetics 
of amphotericin B and mycophenolate mofetil. 
In clinical studies performed in healthy volunteers, 
cyclosporin A (CyA) increased the AUC of caspofungin 
by -35%, probably due to decreased hepatic uptake, 
whereas the plasma levels of CyA remained unchanged. 
In 5 of 12 subjects, co-administration of both drugs 
resulted in an increase in liver enzymes (alanine 
aminotransferase, ALT) of less than or equal to three- 
fold the upper limit of normal, which resolved with 
discontinuation of the product. Pending additional 
clinical data, co-administration of caspofungin and CyA 
is currently not recommended by the manufacturer. 
However, so far, no liver test abnormalities have been 
reported in patients who have been treated anecdotally 
with both drugs. 
Caspofungin decreased the AUC of tacrolimus by 
-25%. However, this problem is manageable through 
standard monitoring of tacrolimus blood levels and 
appropriate dosage adjustments. 
CLINICAL DATA 
The efficacy of caspofungin in locally invasive Cundida 
infections is derived from three comparative clinical 
trials. Two randomized phase II studies (protocol 003 
and 004) provide supportive evidence that caspofungin 
is effective at daily doses of 35, 50 and 70 mg for the 
treatment of mucosal Cundida infections. Protocol 003, 
a multicenter, randomized, double-blind study performed 
in Latin America, compared two doses of caspofungin 
(50 mg and 70 mg) relative to a standard dose of 
conventional amphotericin B (0.5 mgikg) for 14 days 
in 128 predominantly HIV-seropositive patients with 
endoscopically documented symptomatic Candida 
esophagitis.47 Candidu albicans was the predominant 
pathogen (84%), with MICs ranging from 0.06 to 
2 yg/mL. All treatment regimens were highly effective in 
achieving favorable combined clinical and endoscopic 
responses (modified intention-to-treat analysis), although 
the response rate (resolution of symptoms and signi- 
ficant reduction in endoscopic lesions 14 days after 
completing therapy) was highest for those receiving 
caspofungin at 70 mg (89%) and lowest for the 
amphotericin B group (63%). Patients treated with 
caspofungin also had a slightly higher rate of micro- 
biological eradication. In protocol 004, patients with 
oropharyngeal candidiasis (OPC) or esophageal 
candidiasis (EC) received caspofungin 35, 50 or 70 mg 
daily, or amphotericin B 0.5 mg/kg per day, for a 
minimum duration of 7 days (OPC) to 10 days (EC).48 
The response rates for each of the three tested doses of 
caspofungin (complete resolution of symptoms and 
significant reduction in endoscopic or oropharyngeal 
lesions) was numerically higher than seen with ampho- 
tericin B at 0.5 mg/kg, although the daily 70-mg dose of 
caspofungin failed to show any additional benefit. Since 
both studies were designed as ‘proof of concept’ trials, 
these protocols could not demonstrate therapeutic 
equivalence or superiority to amphotericin B. 
The information from phase II studies and the 
pharmacokinetic studies, as well as data from in vitro 
susceptibility testing, led to the selection of a 50-mg dose 
for a phase III comparative study of caspofungin versus 
fluconazole in Cundida esophagitis. This study showed 
that caspofungin 50 mg daily was as effective as 
fluconazole 200 mg daily. The favorable overall com- 
bined response was approximately 80-85% in both 
treatment arms.4g 
Data on the efficacy of caspofungin in invasive 
candidiasis (IC) and Cundidu fungemia have recently 
been presented. Patients with IC were randomized to 
caspofungin (70 mgx 1, then 50 mg/day) or amphotericin 
B (0.6-1.0 mglkgiday). In the primary analysis, caspofungin 
was equivalent to amphotericin B in terms of efficacy, 
although it was far better tolerated than amphotericin 
B. In a predefined secondary analysis (at least 5 days 
of therapy), caspofungin proved to be superior to 
amphotericin B.50 
The efficacy of caspofungin in aspergillosis comes 
from the preliminary analysis of an ongoing multicenter, 
non-comparative phase II salvage study involving 
56 immunocompromised patients with a diagnosis of 
definite or probable pulmonary aspergillosis or definite 
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extrapulmonary disease. 51 Forty-six patients were 
refractory to at least 7 days of standard anti-Aspergillus 
therapy, including conventional amphotericin B or a 
lipid formulation, itraconazole, or an investigational 
azole with anti-Aspergillus activity. Half of the patients 
had received more than 14 days of therapy, and one- 
third received more than 3 weeks of previous therapy. 
Ten patients were enrolled because of intolerance to 
standard antifungal therapy, mainly nephrotoxicity. 
The site of infection and the underlying conditions 
are shown in Figures 2 and 3. All patients received an 
intravenous loading dose of caspofungin of 70 mg, 
followed by a daily dose of 50 mg for up to 162 days 
(mean 31 days). An independent expert panel assessed 
response. A complete (resolution of all attributable 
symptoms, signs, and radiographic or bronchoscopic 
abnormalities) or partial (clinically meaningful improve- 
ment in attributable symptoms, signs, and radiographic 
or bronchoscopic abnormalities) response occurred in 
41% of the patients who received at least one dose of 
caspofungin. As expected, patients who did not tolerate 
previous antifungal therapy had a better outcome (70%) 
than those who were refractory at enrollment (34%). 
Favorable outcomes have been documented across all 
degrees of immunodeficiency, including the persistently 
neutropenic patient. Compared to a well-balanced 
historical control group, caspofungin was more commonly 
associated with favorable outcomes than standard 
therapy (OR 3.6); this effect was consistent across 
subgroups in both adjusted and unadjusted analyses.52 
Results from these 56 patients formed the basis for 
regulatory approval of caspofungin as salvage therapy in 
invasive aspergillosis. The updated report on the first 90 
patients confirmed the efficacy (favorable response rate 
of 45%).53 
An international phase III study comparing 
caspofungin with ambisome in the empirical treatment 
of febrile neutropenia refractory to broad-spectrum 
antibacterials is currently being analyzed. 
TOLERABILITY AND SAFETY 
To date, caspofungin has been generally well tolerated 
both in healthy subjects from the clinical pharmacology 
studies and in patients with a wide spectrum of diseases 
and many concomitant medications included in clinical 
trials. In clinical studies of patients with invasive 
aspergillosis, caspofungin was well tolerated for treatment 
durations up to 162 days, and the favorable safety profile 
was maintained with extended therapy (>28 days). 
Drug-related clinical adverse experiences were typically 
mild and self-limited, and included fever, headache, 
phlebitis, and rash. sl. Among the patients who received 
50 mg or 70 mg of caspofungin in Cundida studies, 
phlebitis was the most commonly reported local in- 
jection site adverse reaction. In comparative studies, 
phlebitis occurred with an incidence of 12% and 22% in 
patients receiving, respectively, caspofungin 50 mg and 
amphotericin B 0.5 mg/kg. In controlled phase II 
Candida infection studies, significantly fewer patients 
in the study arms receiving caspofungin than in the 
amphotericin B arm developed fever or chills.47 The 
clinical safety profile of caspofungin mimicked that of 
fluconazole in the phase III Candida esophagitis study. 
Overall, significantly fewer subjects receiving caspofungin 
than amphotericin B discontinued therapy because of 
adverse events (4% versus 24% in protocol O03).47 
The most frequent drug-related laboratory adverse 
effects were liver function test abnormalities (-10%) 
which occurred at rates similar to those with fluconazole, 
I Hematological 
malignancies 
0 Allogeneic BMT/PSC 
Organ transplant 
q Solid tumor 
Corticosteroids 
Other/None 
Figure 2. Underlying disease in patients with invasive aspergillosis. BMT, bone marrow transplant. PSC, peripheral blood stem cell 
transplantation. 
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Figure 3. Site of infection in patients with invasive aspergillosis. 
and decreases in hemoglobin and hematocrit. Most of 
the elevations in hepatic enzyme levels were transient 
and did not limit therapy. In an in vitro hemolysis assay, 
caspofungin was found to be relatively non-hemolytic 
against human red blood cells (similar to distilled water, 
and less toxic than low doses of amphotericin B). 
Also, in contrast to the case with amphotericin B, drug- 
related elevations in serum creatinine were extremely 
uncommon (1.4%) in caspofungin-treated subjects, and 
similar to those seen with fluconazole. In the three 
completed clinical trials for EC and OPC, there were 
no serious drug-related adverse experiences and few 
adverse experiences leading to discontinuation of 
therapy in the caspofungin recipients.47-49 
In the Aspergihs salvage study, 14% of patients 
had adverse reactions that were judged to be related 
to caspofungin therapy. The following clinical adverse 
events occurred with an incidence greater than 2%: 
fever, nausea, vomiting, and phlebitis. Laboratory abnor- 
malities related to caspofungin that occurred in more 
than one subject included eosinophilia (n=2), proteinuria 
(n=3), increased alkaline phosphatase (n=3), and 
hypokalemia (n=2). Overall, three severe adverse 
experiences were reported as drug-related: one case of 
hypercalcemia, and one case of pulmonary infiltrates 
in a transplant recipient who received multiple anti- 
microbial agents, s1 in addition, there was one case of 
reversible anaphylaxis in the compassionate use program. 
CONCLUSION 
Caspofungin, the first in a new class of antifungal agents, 
is currently approved in the USA, Mexico, Brazil, 
Argentina, Puerto Rico, Peru, New Zealand, Australia 
n Pulmonary (definite) 
0 Pulmonary (probable) 
q Disseminated 
Sinus 
Central nervous system 
and Europe for the treatment of patients with Aspergillus 
infections refractory to other antifungal therapies, or 
who are intolerant to these therapies. Approval for 
Can&da infections is pending. Considering all of the 
efficacy and safety data, caspofungin offers a potential 
benefit to many patients who have otherwise limited 
therapeutic options. The availability of fungal cell wall 
inhibitors will allow future studies examining combina- 
tion with other antifungal drugs and/or cytokines.5”57 
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